Brilliant Violet 510™ anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30F11_BV510_CD45_Antibody_FC_083112
C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 510™.
  • 30F11_BV510_CD45_Antibody_FC_083112
    C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Quantity Check Availability Save
103137 125 µL £125
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103138 50 µg £166
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  2. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  3. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  4. Leslie J, et al. 2021. Sci Rep. 11:1415. PubMed
  5. Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed
  6. Li DD, et al. 2022. J Cell Mol Med. 26:2438. PubMed
  7. Agarwalla P, et al. 2022. Nat Biotechnol. 40:1250. PubMed
  8. Yang Z, et al. 2022. Cancer Discov. 12:1942. PubMed
  9. Garnier L, et al. 2022. Sci Adv. 8:eabl5162. PubMed
  10. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  11. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  12. Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed
  13. Wang L, et al. 2023. Oxid Med Cell Longev. 2023:6480848. PubMed
  14. Abu Hejleh AP, et al. 2023. Int J Tryptophan Res. 16:11786469231153111. PubMed
  15. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  16. Allen SD, et al. 2021. Biomaterials. 269:120635. PubMed
  17. Dube CT, et al. 2022. Epigenetics. 17:444. PubMed
  18. Xu J, et al. 2022. Dev Cell. 57:839. PubMed
  19. Hentzschel F, et al. 2022. Sci Adv. 8:eabm7348. PubMed
  20. Kalavska K, et al. 2022. Life (Basel). 12:. PubMed
  21. Michalek S, et al. 2022. EMBO Rep. 23:e54195. PubMed
  22. Jowett GM, et al. 2022. Cell Rep. 40:111281. PubMed
  23. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  24. Olofsen PA, et al. 2022. Cells. 11:. PubMed
  25. Matter AL, et al. 2022. J Immunol. 209:1880. PubMed
  26. Chen X, et al. 2023. Adv Mater. 35:e2210440. PubMed
  27. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  28. Chen R, et al. 2023. Acta Pharm Sin B. 13:128. PubMed
  29. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  30. Veras FP, et al. 2023. Respir Res. 24:66. PubMed
  31. Vaillancourt M, et al. 2023. PLoS Pathog. 19:e1010942. PubMed
  32. Solier S, et al. 2023. Nature. 617:386. PubMed
  33. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  34. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  35. Pitzer Mutchler A, et al. 2023. Front Physiol. 14:1167904. PubMed
  36. Distel JS, et al. 2023. PLoS Pathog. 19:e1011173. PubMed
  37. Mackel JJ, et al. 2022. Front Cell Infect Microbiol. 12:974175. PubMed
  38. Gawish R, et al. 2022. Elife. 11:. PubMed
  39. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  40. Boal-Carvalho I, et al. 2020. EMBO Rep. 21:e50421. PubMed
  41. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  42. Cornax I, et al. 2021. Microorganisms. 9:00. PubMed
  43. Benitez AA, et al. 2020. Commun Biol. 0.371527778. PubMed
  44. Scott CL et al. 2018. Immunity. 49(2):312-325 . PubMed
  45. Lancaster JN, et al. 2019. Nat Commun. 10:2220. PubMed
  46. Zhang K, et al. 2018. PLoS Pathog. 14:e1006925. PubMed
  47. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  48. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  49. Dong L, et al. 2021. Cancer Cell. . PubMed
  50. Pan XX, et al. 2021. Front Cell Dev Biol. 637424:9. PubMed
  51. Li Y, et al. 2021. Basic Res Cardiol. 116:30. PubMed
  52. Poli V, et al. 2021. iScience. 24:103256. PubMed
  53. Matsumoto R, et al. 2021. Front Pharmacol. 12:715752. PubMed
  54. Alam J, et al. 2022. Mucosal Immunol. 15:620. PubMed
  55. Wang L, et al. 2022. Cancer Res Commun. 2:518. PubMed
  56. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  57. Upadhyaya P, et al. 2021. J Immunother Cancer. 9:00. PubMed
  58. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  59. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  60. Di Gioia M, et al. 2020. Nat Immunol. 21:42. PubMed
  61. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  62. Lees JG, et al. 2020. PLoS One. 15:e0238164. PubMed
  63. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  64. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  65. Sun Q, et al. 2022. Cell Death Dis. 13:724. PubMed
  66. Yu M, et al. 2021. J Clin Invest. 131:. PubMed
  67. Ma M, et al. 2021. Front Immunol. 12:718779. PubMed
  68. Xu Y, et al. 2021. Stem Cell Res Ther. 12:112. PubMed
  69. Yoshihara E, et al. 2020. Nature. 606:586. PubMed
  70. Huang X, et al. 2020. Cell Host Microbe. 29(2):210-221.e6. PubMed
  71. LaMarche NM, et al. 2020. Cell Metabolism. 32(2):243-258.e6. PubMed
  72. Cuff AO, et al. 2020. Frontiers in Immunology. 1.930555556. PubMed
  73. Thanabalasuriar A et al. 2019. Cell Host Microbe. 25(4):526-536 . PubMed
  74. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  75. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  76. Wang H, et al. 2021. Malar J. 20:249. PubMed
  77. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  78. Taguchi K, et al. 2015. J Urol. . PubMed
  79. Duc D et al. 2019. Cell Rep. 29(2):378-390 . PubMed
  80. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  81. Thiriot A et al. 2017. BMC biology. 15(1):45 . PubMed
  82. Knolle MD et al. 2018. Frontiers in immunology. 1.925 . PubMed
  83. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  84. Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed
  85. Bonnardel J, et al. 2019. Immunity. 51:638. PubMed
  86. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  87. Taguchi K, et al. 2014. J Am Soc Nephrol. 25:1680. PubMed
  88. Tyagi AM, et al. 2021. eLife. 10:00. PubMed
  89. Neupane AS, et al. 2020. Cell. 183(1):110-125.e11. PubMed
  90. Yang P, et al. 2022. Nat Commun. 13:5782. PubMed
  91. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  92. Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed
  93. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  94. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  95. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  96. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  97. Dang MT, et al. 2021. Cell Reports. 34(13):108917. PubMed
  98. Nagai M, et al. 2020. Cell. 178(5):1072-1087.e14.. PubMed
  99. Jacobson A et al. 2018. Cell host & microbe. 24(2):296-307 . PubMed
  100. Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
  101. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  102. Lima-Junior DS, et al. 2021. Cell. . PubMed
  103. Alam J, et al. 2021. Front Immunol. 12:701415. PubMed
  104. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  105. Kalavska K, et al. 2021. Int J Mol Sci. 22:. PubMed
  106. Guilliams M, et al. 2022. Cell. 185:379. PubMed
  107. Frenis K, et al. 2021. Basic Res Cardiol. 31:116. PubMed
  108. Dewi IMW, et al. 2021. Cell Reports Medicine. 2(5):100289. PubMed
  109. Walsh SM, et al. 2021. eLife. 10:00. PubMed
  110. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  111. Xiao Y, et al. 2018. Int Immunol. 30:457. PubMed
  112. Stacy A, et al. 2021. Cell. 184(3):615-627.e17. PubMed
  113. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  114. Ayari A, et al. 2020. Commun Biol. 3:237. PubMed
  115. Dang MT, et al. 2021. STAR Protoc. 2:100957. PubMed
  116. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  117. Kalavska K, et al. 2022. Front Oncol. 12:858797. PubMed
  118. Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed
  119. Zeis P, et al. 2020. Immunity. 53:775. PubMed
  120. Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
  121. Holm J, et al. 2015. PLoS One. 10:125495. PubMed
  122. Jordan S, et al. 2020. Cell. 178(5):1102-1114.e17.. PubMed
  123. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  124. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  125. Tian Y, et al. 2020. JCI Insight. 5:00. PubMed
  126. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  127. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  128. Carlson PM, et al. 2021. J Immunol. 207:720. PubMed
  129. Seki N, et al. 2022. iScience. 25:104838. PubMed
  130. Chen H, et al. 2022. Mol Ther Methods Clin Dev. 27:431. PubMed
  131. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
  132. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  133. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  134. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  135. Silva DA, et al. 2019. Nature. 565:186. PubMed
  136. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
  137. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  138. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  139. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  140. Zamarin D, et al. 2020. Clin Cancer Res. 26:4531. PubMed
  141. Domanska D, et al. 2022. J Exp Med. 219:. PubMed
  142. Liu J, et al. 2022. Nat Commun. 13:4308. PubMed
  143. Aulova KS, et al. 2022. Molecules. 27:. PubMed
  144. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  145. Smith LK, et al. 2021. Elife. 10:. PubMed
  146. Catrysse L, et al. 2021. Cell Rep. 36:109748. PubMed
  147. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  148. Xia L, et al. 2021. Cell Chemical Biology. 28(5):610-624.e5. PubMed
  149. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  150. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  151. Wunderlich CM, et al. 2018. Nat Commun. 9:1646. PubMed
  152. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  153. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  154. Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed
  155. Tripathi A, et al. 2021. Mol Psychiatry. 26:3043. PubMed
  156. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  157. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  158. Figueiredo CA, et al. 2022. J Neuroinflammation. 19:17. PubMed
  159. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
  160. Sfakianos JP, et al. 2020. Nat Commun. 2.222222222. PubMed
  161. Deniset JF et al. 2019. Immunity. 51(1):131-140 . PubMed
  162. Weinstock A, et al. 2019. Immunometabolism. 1. PubMed
RRID
AB_2561392 (BioLegend Cat. No. 103137)
AB_2563061 (BioLegend Cat. No. 103138)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV™ 395 anti-mouse CD45 30-F11 FC
Go To Top Version: 2    Revision Date: 05/14/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account